Is transdermal delivery achievable for levodopa? Microarray patch for Parkinson’s disease treatment
Thursday, July 17, 2025
6:08 PM - 6:19 PM EDT
Location: 121 B/C
Introduction: Parkinson’s disease (PD) poses a significant healthcare concern, affecting around 10 million people globally1. Levodopa (LD) is the most efficacious and gold standard PD therapy, whereas a major issue associated is the ‘off’ period complications such as rapid fluctuation between good and poor symptom management, which is believed to be the result of the fluctuating pharmacokinetics of LD following oral administration1. The frequent administration could also be challenging for PD patients2. Thus, we proposed a dissolving microarray patch-based approach for continuous transdermal delivery of LD.
Learning Objectives:
At the completion of this activity, participants will know
Investigate a minimally-invasive transdermal approach for levodopa and carbidopa delivery.
Perform in vitro and in vivo evaluation of the levodopa and carbidopa dissolivng microarray patches.
Demonstrate the benefits of using levodopa microarray patch as an alternative to oral formulations.
Lalitkumar Vora – Lecturer, School of Pharmacy, The Queen's University of Belfast; Jiawen Wang – Research Fellow, School of Pharmacy, The Queen's University of Belfast; Akmal Sabri – Postdoctoral Research Fellow, School of Pharmacy, University of Nottingham; Andrew Graham – Postgraduate Researcher, School of Pharmacy, The Queen's University of Belfast; Ryan Donnelly – Professor, School of Pharmacy, The Queen's University of Belfast
